Clinical Trial Details
| Trial ID: | L5784 |
| Source ID: | NCT01729156 |
| Associated Drug: | Metformin |
| Title: | Effects of Metformin on Hepatic FFA Metabolism |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT01729156/results |
| Conditions: | Type 2 Diabetes|Dyslipidemia |
| Interventions: | DRUG: Metformin|DRUG: Placebo |
| Outcome Measures: | Primary: Hepatic Fatty Acid Oxidation, Hepatic fatty acid oxidation assessed by dynamic C11-palmitate PET, 90 days|Hepatic Fatty Acid Reesterification, Hepatic fatty acid reesterification assessed by C11-palmitate PET, 90 days|Hepatic Fatty Acid Uptake, Hepatic fatty acid uptake assessed by C11-palmitate PET, 90 days|VLDL-TG Secretion, Hepatic VLDL-TG secretion assessed by \[1-14C\] VLDL tracer, 90 days|Whole Body Glucose Rd, Whole body basal glucose metabolism assessed by \[3-3H\]glucose tracer kinetics, 90 days | Secondary: Fatty Acid Turnover, Fatty acid turnover assessed as whole body C11-palmitate turnover, 90 days|VLDL-TG Oxidation, VLDL-TG oxidation assessed by 14C carbon dioxide (CO2) in exhaled breath, 90 days |
| Sponsor/Collaborators: | Sponsor: Lars Christian Gormsen |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 36 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE |
| Start Date: | 2013-01 |
| Completion Date: | 2017-05-05 |
| Results First Posted: | 2019-10-15 |
| Last Update Posted: | 2019-10-15 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT01729156 |
